Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded by StockNews.com to Buy

StockNews.com upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a hold rating to a buy rating in a report published on Sunday.

Separately, TheStreet lowered Vanda Pharmaceuticals from a c- rating to a d rating in a research report on Thursday, February 8th.

Vanda Pharmaceuticals Trading Up 29.4 %

NASDAQ:VNDA opened at $5.24 on Friday. The firm has a market capitalization of $301.51 million, a price-to-earnings ratio of 106.22 and a beta of 0.76. Vanda Pharmaceuticals has a 1-year low of $3.30 and a 1-year high of $7.00. The business’s fifty day moving average price is $4.17 and its 200 day moving average price is $4.05.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05. Vanda Pharmaceuticals had a return on equity of 0.46% and a net margin of 1.30%. The company had revenue of $45.27 million for the quarter, compared to analyst estimates of $37.00 million. Equities analysts forecast that Vanda Pharmaceuticals will post -0.06 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its stake in Vanda Pharmaceuticals by 4.8% during the 1st quarter. JPMorgan Chase & Co. now owns 363,768 shares of the biopharmaceutical company’s stock valued at $4,114,000 after purchasing an additional 16,716 shares during the period. MetLife Investment Management LLC boosted its stake in Vanda Pharmaceuticals by 56.0% during the 1st quarter. MetLife Investment Management LLC now owns 30,601 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 10,989 shares during the period. Panagora Asset Management Inc. boosted its stake in Vanda Pharmaceuticals by 26.1% during the 1st quarter. Panagora Asset Management Inc. now owns 46,531 shares of the biopharmaceutical company’s stock valued at $526,000 after purchasing an additional 9,642 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Vanda Pharmaceuticals by 14.1% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 48,029 shares of the biopharmaceutical company’s stock worth $543,000 after acquiring an additional 5,922 shares during the period. Finally, Yousif Capital Management LLC lifted its position in shares of Vanda Pharmaceuticals by 2.4% in the 1st quarter. Yousif Capital Management LLC now owns 50,710 shares of the biopharmaceutical company’s stock worth $574,000 after acquiring an additional 1,180 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.